In Reply—Are Eosinophils Needed for Normal Health?
Open Access
- 1 April 2022
- journal article
- letter
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (4) , 805-807
Abstract
No abstract availableFunding Information
- Genzyme
- GlaxoSmithKline
- Amgen
- AstraZeneca
- Sanofi
This publication has 10 references indexed in Scilit:
- Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 YearsThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Eosinophils in Health and Disease: A State-of-the-Art ReviewMayo Clinic Proceedings, 2021
- Eosinophils improve cardiac function after myocardial infarctionNature Communications, 2020
- Successful pregnancy in the setting of eosinophil depletion by benralizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Eosinophils Protect Mice From Angiotensin-II Perfusion–Induced Abdominal Aortic AneurysmCirculation Research, 2020
- Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old ageNature Metabolism, 2020
- Gut eosinophils and their impact on the mucus‐resident microbiotaImmunology, 2019
- Eosinophils: The unsung heroes in cancer?OncoImmunology, 2017
- Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohortsThe Lancet Respiratory Medicine, 2016
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthmaJournal of Allergy and Clinical Immunology, 2010